Bifidobacterium bifidum is enriched in the gut microbiome of patients who respond to cancer treatment, but only selected strains of commercial B. bifidum reduced tumour burden synergistically with therapy in a mouse model.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lee, S.-H. et al. Nat. Microbiol. https://doi.org/10.1038/s41564-020-00831-6 (2021).
Routy, B. et al. Science 359, 91–97 (2018).
Matson, V. et al. Science 359, 104–108 (2018).
Sun, S. et al. Proc. Natl Acad. Sci. USA 117, 27509–27515 (2020).
Alessandri, G., Ossiprandi, M. C., MacSharry, J., van Sinderen, D. & Ventura, M. Front. Immunol. 10, 2348 (2019).
Mager, L. F. et al. Science 369, 1481–1489 (2020).
Shi, Y. et al. J. Exp. Med. 217, e20192282 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Hall, L.J., Robinson, S.D. Bacterial strains augment cancer therapeutics. Nat Microbiol 6, 275–276 (2021). https://doi.org/10.1038/s41564-021-00871-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41564-021-00871-6